SCHEMBL31225914

SCHEMBL31225914

C#CCOCCOCCO[C@]1(C(=O)OC)C[C@H](OC(C)=O)[C@@H](NC(=O)COC(C)=O)[C@H]([C@H](OC(C)=O)[C@@H](CNC(=O)CC2CCC(OC(C)=O)CC2)OC(C)=O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31225324 0.95 — —
SCHEMBL31225495 0.91 — —
SCHEMBL31225259 0.87 CD22 (0.32) —
SCHEMBL29727779 0.87 — —
SCHEMBL31225886 0.86 — —
SCHEMBL31225274 0.85 CD22 (0.38) —
SCHEMBL31225323 0.85 CD22 (0.33) —
SCHEMBL31225856 0.85 CD22 (0.33) —
SCHEMBL31225185 0.85 CD22 (0.34) —
SCHEMBL31225758 0.85 CD22 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 — — US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 — — WO disclosed
Send feedback